Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 139

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 139
---
 strategic goals, objectives and targets over the applicable periods, and will be subject to operational and execution risks associated therewith. The Management Projections reflect
assumptions as to certain business decisions that are subject to change. Important factors that may affect actual results and cause the Management Projections not to be achieved include, among others, Enfusion’s ability to successfully expand
into Enfusion’s existing markets and into new markets; anticipated trends and growth rates in Enfusion’s business and in the markets in which Enfusion operates; Enfusion’s ability to retain existing clients and onboard new clients;
Enfusion’s ability to sell additional products and services to Enfusion’s clients; Enfusion’s ability to successfully identify, integrate, and realize the benefits of strategic acquisitions or partnerships; Enfusion’s ability to
effectively manage Enfusion’s growth and future expenses; Enfusion’s anticipated investments in Enfusion’s business; Enfusion’s anticipated capital expenditures; Enfusion’s estimates regarding Enfusion’s capital
requirements; Enfusion’s ability to maintain the security and availability of the products and services that comprise Enfusion’s solution; Enfusion’s ability to maintain, protect, and enhance Enfusion’s intellectual property;
Enfusion’s ability to comply with modified or new laws and regulations applying to Enfusion’s business; the attraction and retention of qualified employees and key personnel; the impact of global financial, economic, public health, and
political events on Enfusion’s business and industry; Enfusion’s ability to compete effectively with existing competitors and new market entrants; and the other risks identified in Enfusion’s SEC filings, including its Annual Report
on Form 10-K for the fiscal year ended December 31, 2023, its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024,
June 30, 2024 and September 30, 2024, and subsequent filings with the SEC, as well as the section titled “Cautionary Note Regarding Forward-Looking Statements” in this Proxy Statement/Prospectus. Additional factors that may
impact us or Enfusion’s business can be found in the various risk factors included in Enfusion’s periodic filings with the SEC. All of these factors are difficult to predict, and many of them are outside of Enfusion’s control. As a
result, there can be no assurance that the Management Projections will be realized, and actual results may be materially better or worse than those contained in the Management Projections. The Management Projections may differ from